Reed Jobs Bets on AI and Philanthropy to Accelerate Cancer Cures

Reed Jobs is building a venture firm focused solely on oncology to create new cancer treatments from early research.

He launched Yosemite three years ago and now manages a team of 17 people while raising a second fund targeting 350 million dollars.

Yosemite's Unique Approach Blends Grants and Investments

The firm uses some no-strings-attached philanthropy to support academic labs before turning promising ideas into companies.

This model has already produced portfolio firms like Azalea from Jennifer Doudna's work and Quarry using induced proximity techniques.

Jobs sees AI speeding up drug discovery and clinical trials by handling repetitive tasks and identifying new targets that were once impossible to drug.

One promising area involves reviving the p53 gene which is often disabled in many cancers and could become a major breakthrough if successful.

Broader Impact on Patients and the Industry

These efforts matter because faster cures and better trial designs could reduce the high costs that currently limit access to new therapies for everyday people.

Patent expirations at big pharma companies are creating more acquisition opportunities that could bring additional resources to early innovators like Yosemite.

Reed Jobs also advocates for stronger government support of basic research noting that even small increases in funding could unlock decades of stalled progress.

Overall the combination of technology and targeted capital suggests a more optimistic future where cancer becomes more manageable sooner than expected.

His focus remains squarely on scientific results rather than personal background showing how dedication to one disease area can drive meaningful change.